EBS stock forecast
Our latest prediction for Emergent BioSolutions, Inc.'s stock price was made on the Sept. 24, 2020 when the stock price was at 99.11$.
In the short term (2weeks), EBS's stock price should underperform the market by -0.66%. During that period the price should oscillate between -6.63% and +7.44%.
In the medium term (3months), EBS's stock price should outperform the market by 0.39%. During that period the price should oscillate between -21.39% and +16.99%.Get email alerts
Create a solid portfolio with EBS
About Emergent BioSolutions, Inc.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
At the moment the company generates 1259M USD in revenues.
On its last earning announcement, the company reported a profit of 3.24$ per share.
The book value per share is 18.76$
Three months stock forecastSept. 24, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|